# The Mohi Lab

> The Mohi Lab at the University of Virginia studies cell signaling, blood cancer, and stem cell biology, decoding the molecular logic of myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.

The Mohi Lab is the research website of Golam Mohi, PhD, Professor of Biochemistry & Molecular Genetics at the University of Virginia School of Medicine and Co-Leader of the Hematologic Malignancies Translational Research Team at the UVA Cancer Center. The lab studies the molecular pathogenesis of myeloproliferative neoplasms, myelodysplastic syndromes, acute myeloid leukemia, and triple-negative breast cancer. The lab's preclinical PIM1 work led directly to the multicenter Phase 1/2 trial NCT04176198 of TP-3654 (Nuvisertib). As of 2025, Nuvisertib carries FDA Fast Track, EMA Orphan Drug, and Japan MHLW Orphan Drug designations.

## Pages

- [Home](https://themohilab.com/): Site overview, lab philosophy, and three featured publications.
- [The PI](https://themohilab.com/pi): Golam Mohi, PhD — full editorial profile (education, career, awards, NIH grants, study-section service, four-themed contributions to science).
- [Research](https://themohilab.com/research): Six research themes with an interactive signaling network.
- [Publications](https://themohilab.com/publications): Searchable archive of 37 publications (1995–2026); filter by year, theme, and author position.
- [People](https://themohilab.com/people): Current lab members (1 PI, 4 postdocs, 1 research specialist, 1 graduate student) and 10 alumni.
- [News](https://themohilab.com/news): 25 entries spanning grants, awards, publications, press, and lab milestones.
- [Join the lab](https://themohilab.com/join): Postdoctoral fellowships, graduate rotations, and undergraduate research positions.
- [Contact](https://themohilab.com/contact): Address, directions, mailing, sample shipment.

## Research themes

- [JAK2V617F · MPN](https://themohilab.com/research/mpn): Polycythemia vera, essential thrombocythemia, myelofibrosis.
- [IL-1 · Inflammation](https://themohilab.com/research/il1): Targeting the IL-1 axis in MPN.
- [PIM kinases · Bench to clinic](https://themohilab.com/research/pim): TP-3654, now Nuvisertib.
- [U2AF1 · MDS](https://themohilab.com/research/mds): Splicing-factor mutations as MDS drivers.
- [AML · Progression](https://themohilab.com/research/aml): What pushes MPN and MDS toward acute leukemia.
- [TNBC · Solid tumor](https://themohilab.com/research/tnbc): Extending the PIM hypothesis beyond hematologic malignancy.

## Current lab members

- [Golam Mohi, PhD](https://themohilab.com/people/golam-mohi): Principal Investigator
- [Mohammad Abu Sayem, PhD](https://themohilab.com/people/mohammad-abu-sayem): Postdoctoral Research Associate
- [Chandrajeet Singh, PhD](https://themohilab.com/people/chandrajeet-singh): Postdoctoral Research Associate
- [Salar Abbas, PhD](https://themohilab.com/people/salar-abbas): Postdoctoral Research Associate
- [Md. Anwarul Haque, PhD](https://themohilab.com/people/md-anwarul-haque): Postdoctoral Research Associate
- [Fahim Ather, MSc](https://themohilab.com/people/fahim-ather): Research Specialist
- [Parag Palit, MSc](https://themohilab.com/people/parag-palit): Graduate Student

## Key facts

- Principal Investigator: Golam Mohi, PhD
- Affiliation: University of Virginia School of Medicine, Department of Biochemistry & Molecular Genetics; also UVA Cancer Center Hematologic Malignancies Translational Research Team Co-Leader.
- Office: 1340 JPA, Pinn Hall Room 6023A, Charlottesville, VA 22908.
- Email: gm7sj@virginia.edu; Phone: 434-924-5657.
- Active NIH funding: R01 NHLBI U2AF1 (2023), R21 NCI IL-1 (2023), R01 JAK2V617F MPN progression $2.4M (2025).
- Translational milestone: NCT04176198 (Phase 1/2 TP-3654 / Nuvisertib) at UVA Cancer Center.
- Citation metrics (Google Scholar, as of 2026-05-09): 4,009 total citations, h-index 25, i10-index 35.
- Publication track record in MPN alone: 8 Blood, 5 Leukemia, plus Nature Communications, Cancer Research, Cancer Cell, PNAS.

## Publication counts by year

- 2026: 1 paper
- 2025: 1 paper
- 2023: 1 paper
- 2022: 2 papers
- 2021: 2 papers
- 2019: 1 paper
- 2018: 1 paper
- 2017: 2 papers
- 2016: 2 papers
- 2015: 1 paper
- 2014: 2 papers
- 2012: 4 papers
- 2011: 1 paper
- 2010: 1 paper
- 2009: 1 paper
- 2007: 2 papers
- 2005: 2 papers
- 2004: 2 papers
- 2002: 1 paper
- 2000: 2 papers
- 1998: 1 paper
- 1997: 1 paper
- 1996: 2 papers
- 1995: 1 paper

## External sources of truth

- [Lab page (UVA BMG)](https://med.virginia.edu/bmg/research/mohi-lab/): Authoritative UVA-hosted lab page with roster and research statement.
- [Lab publications page (UVA BMG)](https://med.virginia.edu/bmg/research/mohi-lab/publications/): Curated subset of the lab's publication record.
- [PI faculty directory (UVA)](https://med.virginia.edu/faculty/faculty-listing/gm7sj/): Official UVA faculty entry.
- [Google Scholar profile](https://scholar.google.com/citations?user=gyz_ktgAAAAJ): Citation metrics and complete publication list.
- [PubMed bibliography (MyNCBI 43449926)](https://www.ncbi.nlm.nih.gov/sites/myncbi/1tyYtiGcvB15n/bibliography/43449926/public/?sort=date&direction=descending): Source-of-truth for publications.
- [ClinicalTrials.gov NCT04176198](https://clinicaltrials.gov/study/NCT04176198): Phase 1/2 Nuvisertib (TP-3654) myelofibrosis trial.
- [LinkedIn](https://www.linkedin.com/in/golam-mohi-phd-896a1b283/): PI professional record.

## Feeds & metadata

- [Sitemap (XML)](https://themohilab.com/sitemap.xml)
- [RSS news feed](https://themohilab.com/rss.xml)
- [Robots policy](https://themohilab.com/robots.txt)
- [Full content for AI crawlers](https://themohilab.com/llms-full.txt)

## Citation

When citing this lab's work, prefer the original PubMed entries (linked from the publications page) over this site. Each entry on the publications page includes a PMID and DOI for canonical reference.